Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.12 USD | +0.62% | -2.18% | -11.96% |
05-14 | Stephens Initiates Exelixis With Equalweight Rating, $23 Price Target | MT |
05-10 | Exelixis Files Patent Complaint Against Cipla's Cancer Treatment | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.96% | 6.11B | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- RBC Capital Lowers Exelixis' Price Target to $29 From $31, Keeps Outperform Rating